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the SHOCK trial and 260/1189 in the SHOCK registry. We explored the
number of patients meeting criteria for RVD as deﬁned by:
CVP>10mmHg, CVP/PCWP>0.63, PAPi<2.0 and RVSWI<450
mmHg$mL/m2. Next, we explored the number of patients who met
the RR-RVF criteria in the trial and registry. Finally, we examined
whether RVD or the RR-RVF criteria were associated with 30 day
mortality.
RESULTS RVD was observed in 37% and 36% of patients in the SHOCK
trial and registry respectively. RR-RVF criteria were observed in 45%
and 38% of SHOCK trial and registry patients respectively. Among trial
patients, RR-RVF criteria were not associated with increased 30-day
mortality. Among registry patients, 30 day mortality was higher
among patients who met RR-RVF criteria compared to those who did
not (58% vs 44%, p¼0.03). RR-RVF criteria were associated with a
hazard ratio of 1.46[1.03-2.07] (p¼0.04) for 30-day mortality among
registry subjects.CONCLUSIONS RVD was commonly observed among patients in the
SHOCK trial and registry. The RR-RVF criteria were associated with
increased 30-day mortality in both the SHOCK trial and registry. These
ﬁndings suggest that univentricular shock is uncommon in AMI-CS.
Early recognition and aggressive management of RVD may improve
clinical outcomes in AMI-CS. Future studies are required to further
explore the potential clinical utility of the RR-RVF criteria.
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BACKGROUND The use of intra-cardiac assist devices is expanding
and correct position of these devices is required for optimal func-
tioning. The aortic valve is an important landmark for positioning
intra-cardiac assist devices. It would be of great value if the device
position could be determined accurately by plain supine chest X-ray.
We aimed to introduce a ratio for determination of the aortic valve
location on plain supine chest X-ray images in the intensive care unit.
METHODS Supine anterior-posterior chest X-ray of patients with an
aortic valve prosthesis (n¼475) were analyzed to determine thelocation of the aortic valve using the Aortic Valve Location (AVL) ratio.
The AVL ratio was validated using computer tomography of patients
with angina pectoris without known valvular disease (n¼95). The
position of a Impella device was determined on chest X-ray and
compared to echocardiographic images (n¼34).
RESULTS The AVL ratio determines the location of the aortic valve
caudal to the carina, at a distance of 0.270.05 times the thoracic
width. When the AVL ratio is used for assessment of the position of a
cardiac assist device it shows a good correlation with
echocardiography.
CONCLUSIONS The Aortic Valve Location Ratio enables accurate and
reproducible localization of the aortic valve on supine chest X-ray.
This tool is easily applicable and can be used for assessment of cardiac
device position in patients on the Intensive care unit.CATEGORIES CORONARY: Hemodynamic Support and Cardiogenic
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BACKGROUND Refractory cardiogenic shock (RCS) in acute myocar-
dial infarction (AMI) is associated with high mortality rates. Impella
and intra-aortic balloon pump (IABP) provide only limited left ven-
tricular (LV) support. Veno-arterial Extracorporeal membrane
oxygenation (VA-ECMO) and peripheral ventricular assist device,
TandemHeart (p-VAD), have been claimed to provide superior LV
support. However, limited data exists on the outcomes of VA-ECMO
and p-VADs in this speciﬁc population. This study aimed to compare
VA-ECMO and p-VAD in patients presented with RCS complicated by
AMI.
METHODS Using prospective registries, we identiﬁed patients un-
dergoing VA-ECMO or p-VAD placements for an indication of AMI with
RCS. Clinical, procedural and clinical outcomes data were recorded for
both groups. A comparative analysis of use of these two devices in
AMI was performed.
RESULTS In the study there were 35 patients who presented with
RCS. 16 patients were assigned to VA-ECMO and 19 to p-VAD. Baseline
clinical characteristics were similar between the groups except for
higher incidence of diabetes (58% vs. 9%, p¼0.03) in the p-VAD group.
Door to device time was also longer in the p-VAD group. Overall the
survival rate in hospital (58% vs.56%, p¼0.45) and at 30 days (58% vs.
56%, p¼0.3) were similar in both groups. There was no signiﬁcant
difference in the incidence of complications including limb ischemia
requiring surgery, signiﬁcant hemolysis, need for renal replacement
therapy, stroke or recurrent myocardial infarction between the two
B76 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5groups. However, there was a higher incidence of ventricular ar-
rhythmias in the VA-ECMO group (16% vs. 50%, p¼0.02).
CONCLUSIONS Both VA-ECMO and p-VAD had similar survival and
complication rates when used in patients presenting with RCS in AMI.
Choice of device in these patients should be based on operator
expertise and center’s resources.CATEGORIES CORONARY: Hemodynamic Support and Cardiogenic
Shock
KEYWORDS Cardiogenic shock, Extracorporeal membrane oxygena-
tion, TandemHeart
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BACKGROUND We sought to evaluate the outcomes of ECMO
in a variety of clinical settings among patients presenting in
cardiogenic shock and/or respiratory failure and underwent emer-
gent venous-arterial (VA) ECMO and/or venous-venous (VV) ECMO
placement.
METHODS We retrospectively analyzed data from 163 consecutive
ECMOs (21 VV and 142 VA) at the MH CAHF from 2012 to 2014. Mor-
tality and morbidity at discharge were analyzed in relationship to type
of ECMO support VA vs VV.
RESULTS Overall ECMO survival rates at discharge was 40%, however
signiﬁcant difference in terms of mortality and morbidity was
observed between VA and VV groups. In the VV group the median age
was 50 years (IQR 23,57), average length of stay was 33 days (IQR
22,48) median length of support was 8 days (IQR 3,20). VV mortality
was 19% (4 cases). Causes of death were stroke in 1 patient and mul-
tiorgan failure in 3 patients and death occurred after 2, 29,24,35 days,
respectively, after ECMO implantation. Respiratory failure due to
H1N1 led to ECMO implantation in 4 cases and caused the demise of 2
patients (50% mortality). No hypothermia protocol was utilized.
Vascular complications related to access were reported in 5% of the
patients. Stroke prevalence was 14% and led to patient demise in 1case. The longest length of support with successful weaning was 31
days. In the VA group the median age was 61 years (IQR 48,70),
average length of stay was days 16 days (IQR 7,34) median length of
support was 4 days (IQR 1,7). VA mortality was 65%. Refractory
cardiogenic shock was the leading indication to ECMO implantation,
however ECMO was utilized also as bailout strategy in the context of
intraprocedural complications during TAVI in 10 cases, with a 30%
mortality (3 deaths in 10 cases). Hypothermia protocols were utilized
in 20% of the cases. Stroke prevalence was 16%. The longest length of
support with successful weaning was 192 days, the oldest patient to
survive ECMO was 91 years old and median age of patients who sur-
vived ECMO was 62 years (IQR 49,70).
CONCLUSIONS This is a large data series collected from a single
center over the last two years. These results provide additional evi-
dence to support ECMO as a valid option for hemodynamic support in
patients of a selected age group presenting with profound cardiogenic
shock and respiratory failure.
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BACKGROUND Catheterization techniques can offer percutaneous
way of coronary revascularization (PCI), in complex coronary lesions.
In cath-lab we are able to perform high risk procedures, but we are
still limited with circulatory failure at time of PCI. Commercial cir-
culation supports (Impella, TandemHeart or ECMO) are expensive.
We decided to develop cheap, fully percutaneous and easy to use
way of circulatory support for backup at high risk PCI for conscious
patients.
METHODS We modiﬁed standard tubing set for open extracorporeal
circulation, we get out of the tubing kit venous reservoir and con-
nect it only for priming, deairing system and for getting volume.
Femoral artery was pre-closed by 2x ProGlide sutures and cannu-
lated with 18 F cannula, femoral vein was cannulated with 20-22 F
cannula. Blood from right atrium was drawn to the centrifugal
pump, continue to the oxygenator and through arterial ﬁlter back to
femoral artery (Image). UFH was given and circulation started at ACT
400 sec. For PCI we used contralateral groin, pressure was recorded
from sheat sideport. At the end UFH was reversed to ACT 250 sec,
arterial puncure was closed with sutures, venous with manual
compression.
